Estimating the impact of different types of vaccines
Analyses of the returns that both the public and private sectors could anticipate from malaria vaccines are critical to informing decisions related to our portfolio of vaccine candidates. These analyses are also critical to discussions with industrial partners and to preparing potential financing institutions, countries, and other partners for the future implications of malaria vaccines.
During 2005–2006, MVI conducted a first ever analysis of the returns that the public and private sectors could anticipate from malaria vaccines. The Return on Investment for Malaria Vaccines: Preliminary Estimates of Public Health Impact in Africa showed that a partially efficacious vaccine could have a significant impact on the malaria burden. See Investment Case for Malaria Vaccines (111 KB PDF) presentation for more information.
The 2005–2006 analysis is being updated. Working with partners, we are:
- Estimating the public health impact of different types of potential malaria vaccines in order to inform research and development for future vaccines.
- Updating our analysis of the returns that could be anticipated from malaria vaccines with further data garnered from trials of the most clinically advanced malaria vaccine.
- Generating updated data on the returns to public and private sectors and publishing summaries of the innovative methodologies and critical findings.